{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:55:15Z","timestamp":1761893715803},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,7,1]],"date-time":"2002-07-01T00:00:00Z","timestamp":1025481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Renal Replacement Therapy"],"published-print":{"date-parts":[[2002,7]]},"DOI":"10.1053\/jarr.2002.34841","type":"journal-article","created":{"date-parts":[[2002,8,29]],"date-time":"2002-08-29T19:51:36Z","timestamp":1030650696000},"page":"200-208","source":"Crossref","is-referenced-by-count":11,"title":["Future role of calcimimetics in end-stage renal disease"],"prefix":"10.1053","volume":"9","author":[{"given":"William G.","family":"Goodman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stewart A.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/jarr.2002.34841_NEWBIB1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1152\/physrev.2001.81.1.239","article-title":"Extracellular calcium sensing and extracellular calcium signaling","volume":"81","author":"Brown","year":"2001","journal-title":"Physiol Rev"},{"key":"10.1053\/jarr.2002.34841_NEWBIB2","first-page":"1019","article-title":"Calcium receptors as novel drug targets","author":"Nemeth","year":"1996"},{"key":"10.1053\/jarr.2002.34841_NEWBIB3","first-page":"347","article-title":"Renal osteodystrophy in adults and children","author":"Goodman","year":"1999"},{"key":"10.1053\/jarr.2002.34841_NEWBIB4","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1046\/j.1523-1755.2001.0590031187.x","article-title":"Recent developments in the management of secondary hyperparathyroidism","volume":"59","author":"Goodman","year":"2001","journal-title":"Kidney Int"},{"key":"10.1053\/jarr.2002.34841_NEWBIB5","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/S0272-6386(00)70064-3","article-title":"Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management","volume":"35","author":"Block","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/jarr.2002.34841_NEWBIB6","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/ndt\/14.9.2178","article-title":"Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease","volume":"14","author":"Marchais","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/jarr.2002.34841_NEWBIB7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ndt\/15.7.1014","article-title":"Arterial stiffening and vascular calcifications in end-stage renal disease","volume":"15","author":"Gu\u00e9rin","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/jarr.2002.34841_NEWBIB8","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca \u00d7 PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"J Am Soc Nephrol."},{"key":"10.1053\/jarr.2002.34841_NEWBIB9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00041552-199307000-00004","article-title":"Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro","volume":"2","author":"Brown","year":"1993","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/jarr.2002.34841_NEWBIB10","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1210\/jcem.84.11.6236","article-title":"A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure","volume":"84","author":"John","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/jarr.2002.34841_NEWBIB11","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1074\/jbc.273.9.5253","article-title":"RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate","volume":"273","author":"Moallem","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1053\/jarr.2002.34841_NEWBIB12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1210\/jcem-48-4-604","article-title":"Direct comparison in vivo and in vitro of suppressibility of parathyroid function by calcium in primary hyperparathyroidism","volume":"48","author":"Brown","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/jarr.2002.34841_NEWBIB13","first-page":"1489","article-title":"Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism","volume":"76","author":"Ramirez","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/jarr.2002.34841_NEWBIB14","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1073\/pnas.95.7.4040","article-title":"Calcimimetics with potent and selective activity on the parathyroid calcium receptor","volume":"95","author":"Nemeth","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/jarr.2002.34841_NEWBIB15","first-page":"473","article-title":"NPS R-568: A type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium","volume":"290","author":"Fox","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1053\/jarr.2002.34841_NEWBIB16","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1172\/JCI119851","article-title":"The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor","volume":"100","author":"Wada","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1053\/jarr.2002.34841_NEWBIB17","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1681\/ASN.V115903","article-title":"Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats","volume":"11","author":"Chin","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/jarr.2002.34841_NEWBIB18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.1523-1755.2000.00837.x","article-title":"Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism","volume":"57","author":"Wada","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/jarr.2002.34841_NEWBIB19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1523-1755.1998.00782.x","article-title":"NPS R-568 halts or reverses osteitis fibrosa in uremic rats","volume":"53","author":"Wada","year":"1998","journal-title":"Kidney Int"},{"key":"10.1053\/jarr.2002.34841_NEWBIB20","doi-asserted-by":"crossref","first-page":"9831","DOI":"10.1073\/pnas.94.18.9831","article-title":"Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia","volume":"94","author":"Li","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/jarr.2002.34841_NEWBIB21","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1210\/endo.139.10.6262","article-title":"Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice","volume":"139","author":"Li","year":"1998","journal-title":"Endocrinology"},{"key":"10.1053\/jarr.2002.34841_NEWBIB22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/ng1295-389","article-title":"A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism","volume":"11","author":"Ho","year":"1995","journal-title":"Nat Genet"},{"key":"10.1053\/jarr.2002.34841_NEWBIB23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1523-1755.1998.00735.x","article-title":"A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication","volume":"53","author":"Antonsen","year":"1998","journal-title":"Kidney Int"},{"key":"10.1053\/jarr.2002.34841_NEWBIB24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1523-1755.2000.00183.x","article-title":"A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism","volume":"58","author":"Goodman","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/jarr.2002.34841_NEWBIB25","doi-asserted-by":"crossref","first-page":"C382","DOI":"10.1152\/ajpcell.2001.280.2.C382","article-title":"Expression of extracellular calcium-sensing receptor in human osteoblastic MG-63 cell line","volume":"280","author":"Yamaguchi","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1053\/jarr.2002.34841_NEWBIB26","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1006\/bbrc.1998.8178","article-title":"Expression of extracellular calcium (Ca2+o)-sensing receptor in the clonal osteoblast-like cell lines, UMR-106 and SAOS-2","volume":"243","author":"Yamaguchi","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1053\/jarr.2002.34841_NEWBIB27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/00041552-200109000-00005","article-title":"Calcimimetic agents for the treatment of hyperparathyroidism","volume":"10","author":"Goodman","year":"2001","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/jarr.2002.34841_NEWBIB28","first-page":"578A","article-title":"The calcimimetic AMG-073 reduces parathyroid hormone (PTH), phosphorus (P), and calcium \u00d7 phosphorus product (Ca \u00d7 P) in patients with ESRD and secondary hyperparathyroidism","volume":"11","author":"Lindberg","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/jarr.2002.34841_NEWBIB29","first-page":"764A","article-title":"Short-term treatment of secondary hyperparathyroidism with the calcimimetic agent AMG 073","volume":"12","author":"Dr\u00fceke","year":"2001","journal-title":"J Am Soc Nephrol"}],"container-title":["Advances in Renal Replacement Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1073444902700423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1073444902700423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T06:47:32Z","timestamp":1622098052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1073444902700423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["S1073444902700423"],"URL":"https:\/\/doi.org\/10.1053\/jarr.2002.34841","relation":{},"ISSN":["1073-4449"],"issn-type":[{"value":"1073-4449","type":"print"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}